215 related articles for article (PubMed ID: 23442768)
1. Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases.
Young AL; Chalmers CR; Hawcroft G; Perry SL; Treanor D; Toogood GJ; Jones PF; Hull MA
BMC Cancer; 2013 Feb; 13():92. PubMed ID: 23442768
[TBL] [Abstract][Full Text] [Related]
2. miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer.
Monteleone NJ; Moore AE; Iacona JR; Lutz CS; Dixon DA
Sci Rep; 2019 Apr; 9(1):5405. PubMed ID: 30931980
[TBL] [Abstract][Full Text] [Related]
3. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
Backlund MG; Mann JR; Holla VR; Buchanan FG; Tai HH; Musiek ES; Milne GL; Katkuri S; DuBois RN
J Biol Chem; 2005 Feb; 280(5):3217-23. PubMed ID: 15542609
[TBL] [Abstract][Full Text] [Related]
4. 15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes.
Kim SH; Song SE; Baik H; Hur DY; Kang MS; Bae KB
Anticancer Res; 2022 Nov; 42(11):5385-5396. PubMed ID: 36288851
[TBL] [Abstract][Full Text] [Related]
5. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development.
Pereira C; Queirós S; Galaghar A; Sousa H; Pimentel-Nunes P; Brandão C; Moreira-Dias L; Medeiros R; Dinis-Ribeiro M
PLoS One; 2014; 9(4):e92000. PubMed ID: 24694755
[TBL] [Abstract][Full Text] [Related]
6. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury.
Yao L; Chen W; Song K; Han C; Gandhi CR; Lim K; Wu T
PLoS One; 2017; 12(4):e0176106. PubMed ID: 28423012
[TBL] [Abstract][Full Text] [Related]
7. Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.
Kochel TJ; Fulton AM
Prostaglandins Other Lipid Mediat; 2015; 116-117():99-103. PubMed ID: 25433169
[TBL] [Abstract][Full Text] [Related]
8. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins.
Lu D; Han C; Wu T
J Biol Chem; 2013 Jul; 288(27):19484-502. PubMed ID: 23687300
[TBL] [Abstract][Full Text] [Related]
9. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P
Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207
[TBL] [Abstract][Full Text] [Related]
10. A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
Mehdawi LM; Satapathy SR; Gustafsson A; Lundholm K; Alvarado-Kristensson M; Sjölander A
Oncotarget; 2017 May; 8(21):35033-35047. PubMed ID: 28402256
[TBL] [Abstract][Full Text] [Related]
11. Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation.
Hamza A; Cho H; Tai HH; Zhan CG
Bioorg Med Chem; 2005 Jul; 13(14):4544-51. PubMed ID: 15908215
[TBL] [Abstract][Full Text] [Related]
12. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Smartt HJ; Greenhough A; Ordóñez-Morán P; Talero E; Cherry CA; Wallam CA; Parry L; Al Kharusi M; Roberts HR; Mariadason JM; Clarke AR; Huelsken J; Williams AC; Paraskeva C
Gut; 2012 Sep; 61(9):1306-14. PubMed ID: 22082586
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 regulates its own inactivating enzyme, 15-PGDH, by EP2 receptor-mediated cervical cell-specific mechanisms.
Kishore AH; Owens D; Word RA
J Clin Endocrinol Metab; 2014 Mar; 99(3):1006-18. PubMed ID: 24471568
[TBL] [Abstract][Full Text] [Related]
14. 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
Miyoshi J; Yajima T; Shimamura K; Matsuoka K; Okamoto S; Higuchi H; Funakoshi S; Takaishi H; Hibi T
Anticancer Res; 2012 Apr; 32(4):1193-202. PubMed ID: 22493349
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
16. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.
Hughes D; Otani T; Yang P; Newman RA; Yantiss RK; Altorki NK; Port JL; Yan M; Markowitz SD; Mazumdar M; Tai HH; Subbaramaiah K; Dannenberg AJ
Cancer Prev Res (Phila); 2008 Sep; 1(4):241-9. PubMed ID: 19138967
[TBL] [Abstract][Full Text] [Related]
17. 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1.
Lu D; Han C; Wu T
Oncogene; 2014 Feb; 33(9):1101-12. PubMed ID: 23542179
[TBL] [Abstract][Full Text] [Related]
18. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Kochel TJ; Reader JC; Ma X; Kundu N; Fulton AM
Oncotarget; 2017 Jan; 8(4):6540-6554. PubMed ID: 28029661
[TBL] [Abstract][Full Text] [Related]
19. Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window.
Nayak NR; Sengupta J; Ghosh D
Contraception; 1998 Aug; 58(2):111-7. PubMed ID: 9773266
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E
Kim HB; Kim M; Park YS; Park I; Kim T; Yang SY; Cho CJ; Hwang D; Jung JH; Markowitz SD; Hwang SW; Yang SK; Lim DS; Myung SJ
Gastroenterology; 2017 Feb; 152(3):616-630. PubMed ID: 27864128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
